On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
The immune system consists of two parts: innate immunity and adaptive immunity. T cells and B cells in the adaptive immune system are two major players to mount an antigen-specific defense and offer long-term protection. However, due to the immune tolerance and immunodominance mechanisms, some T cells and B cells can recognize the antigens but couldn’t develop effective immune responses.
My research focus is using synthetic biomaterials to engineer the innate immune system and unlock the non-responsive adaptive immune repertoire for new cancer immunotherapies and infectious disease vaccines. In this seminar, two examples illustrating my research work will be described. In the first example, I develop a toll-like receptor 7 agonist-based nanoparticle (TLR7-NP) adjuvant to alter germinal center (GC) signaling and induce high levels of cross-reactive antibody responses to multiple heterologous viral variants of influenza and SARS-CoV-2.
The second example is to design a nanoparticle platform to reverse the anergy of tumor infiltrating self-specific CD8+ T cells for creating a new and effective immunotherapeutic strategy for treating broad cancer patients.
